TY  - JOUR
AU  - Kaló, Zoltán
AU  - Petykó, Zsuzsanna Ida
AU  - Fricke, Frank-Ulrich
AU  - Maniadakis, Nikos
AU  - Tesař, Tomáš
AU  - Podrazilová, Kateřina
AU  - Espin, Jaime
AU  - Inotai, András
PY  - 2021
DO  - 10.1186/s12962-021-00296-2
SN  - 1478-7547
UR  - http://hdl.handle.net/10668/18202
T2  - Cost effectiveness and resource allocation : C/E
AB  - A core evaluation framework that captures the health care and societal benefits of value added medicines (VAMs, also often called repurposed medicines) was proposed in Report 1, aiming to reduce the heterogeneity in value assessment processes across...
LA  - en
KW  - Drug repurposing
KW  - Evidence
KW  - Generic reference pricing
KW  - Incremental innovation
KW  - Multi-criteria decision analysis
KW  - Value assessment framework
KW  - Value-added medicines
TI  - Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives.
TY  - research article
VL  - 19
ER  -